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To purify and identify the novel androgen receptor cofactors in prostate cancer cells 
(前立腺癌における新規アンドロゲン受容体転写共役因子群の精製及び機能解析) 
 
 
 
 
 
Chapter 1 Introduction 
 
The male sex hormone androgens are critical for expression of male phenotype 
including development and maintenance of secondary male characteristics. The 
physiological effects are outputted via diverse genes expression that are mainly 
mediated by its cognate receptor, androgen receptor (AR) which is a ligand-inducible 
transcription factor. Due to the extensive physiological role of AR, abnormal AR signaling 
is implicated in a wide variety of disorders including prostate cancer. 
AR signaling start from the circulating androgens directly penetrate across cell 
membrane of target cells and bind to the inactive cytoplasmic AR. The androgen-bound 
AR undergoes conformational change, dimerization and translocates from cytosol to the 
nucleus where it binds to specific DNA sequences known as androgen-responsive 
elements (AREs) and recruits a series of coregulators (also termed cofactors) that exhibit 
distinct functions to regulate a vast number of target genes transcription. 
More than 150 AR coregulators have been identified through basic molecular and 
biochemical approaches. Recent studies revealed the crucial role of chromatin 
architecture in gene regulation and also emerged many of these AR coregulators mediate 
transcription through building appropriate chromatin environment. On the other hand, 
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it has implicated that the posttranslational modifications of AR or AR complex 
components have a critical role for quantitative /qualitative regulation of AR. However, 
the mechanism by which these coregulators regulate AR posttranslational modifications 
and affect target genes expression is ill-defined.  
In addition, given the advance of global genome-wide mapping technology, the function 
of AR coregulators as well as their specific target genes have been analyzed and brought 
new insights into AR transcriptional regulation. 
The aim of these study is to reveal a novel AR transcriptional regulation mechanism 
by identifying AR coregulators. For this purpose I adopted biochemical purification of 
the AR-associated proteins, and investigated the AR quantitative /qualitative regulation 
as well as the global genome-wide transcript profiling by which these coregulators. 
 
Chapter 2 Identification of novel AR transcriptional coregulators in prostate 
cancer cells 
 
Identification of the AR-associated proteins using antibody affinity purification  
  To purify the AR-associated proteins in prostate cancer cells, I performed the anti-AR 
antibody affinity protein purification. The endogenous AR-associated proteins were 
subjected to LC-MS/MS analysis. In addition to the known AR coregulator PRMT5, 
several proteins were identified as AR coregulator candidates. Among these candidates, 
Ubiquitin Specific Protease 7 (USP7) was focused because of its high score identified by 
LC-MS/MS.  
Ubiquitination is a reversible posttranslational modification that provides a tag either 
marking the labeled protein for degradation or modulates its function. Ubiquitination 
can be reversed by deubiquitinating enzymes (DUBs) such as USP7 through removing 
ubiquitin from target proteins. It is known that ligand-dependent ubiquitination of AR 
plays an important role in AR transcriptional regulation, including act as a scaffold for 
coactivators recruitment or transcriptional activation-coupled proteasomal degradation. 
However, the precise mechanism by which these ubiquitin network mediate AR 
transcriptional activity is poorly understood. To investigate the role of USP7 in AR 
transcriptional regulation may be helpful to clear the intricate ubiquitin network in AR 
signaling. 
 
USP7 is a novel AR-associated protein in prostate cancer cells 
To validate the interaction between USP7 and AR, co-immunoprecipitation was 
performed in potent androgen DHT-treated prostate cancer cells LNCaP and 22Rv1. The 
6 
 
result confirmed the LC-MS/MS identification and revealed that the interaction of USP7 
and AR was DHT-dependently enhanced. To investigate whether USP7 modulates the 
ubiquitination of AR, in vivo ubiquitination assay was carried out. As a result, 
overexpression of USP7 attenuated ubiquitinated AR produced by DHT, suggesting 
USP7 may participate in AR transcriptional activity regulation through control of AR 
ubiquitination status. 
 
Chapter 3 The elucidation of USP7 functional role in AR transcriptional 
regulation 
 
USP7 associates with AR on AREs upon rapid DHT stimulation 
  Previous studies indicated that USP7 mainly localizes in nucleus, hence the 
investigation was focused on chromatin region. The time course recruitment of USP7 to 
AREs was assessed using ChIP-qPCR. The recruitment of USP7 to AREs increased upon 
1 hr DHT treatment and declined rapidly, suggesting USP7 was involved in the early 
stage of AR transcriptional activation. In addition, the interaction of USP7 and AR on 
AREs was confirmed using re-ChIP. This result exhibited that the association and 
disassociation of USP7 and AR on AREs upon rapid DHT stimulation. 
 
USP7 regulates AR transcriptional activity and specificity 
  Given the gene specific regulation manner of AR coregulators, I profiled the global 
effect of USP7 knockdown on androgen-dependent genes transcript using RNA-seq 
analysis. 
Approximately 45% of androgen-dependent genes expression were affected by USP7 
knockdown, indicating the essential role of USP7 in AR signaling. In addition, USP7 
functioned as a coactivator in DHT up-regulated genes, whereas it acted as a corepressor 
in DHT down-regulated genes. This result suggested that USP7 is able to mediate AR 
transcriptional activity and specificity.  
 
USP7 regulates liganded AR protein stability and chromatin recruitment 
To investigate the mechanism by which USP7 regulates AR transcriptional activity, I 
observed the effect of USP7 knockdown on AR chromatin recruitment. The result 
indicated that AR binding to AREs was diminished by USP7 knockdown. Since USP7 
attenuated ligand-induced ubiquitinated AR, it was expected that USP7 facilitates AR 
chromatin binding through receptor stabilization. To corroborate this speculation, I 
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observed the effect of USP7 overexpression on liganded AR protein degradation rates. 
The result revealed that the liganded AR protein half-life was prolonged by USP7.  
 
Chapter 4 Conclusion and Discussion 
 
To decipher the new AR transcriptional regulation mechanism, the endogenous AR-
associated proteins in prostate cancer cells were affinity purified, and the DUBs USP7 
was identified as a novel AR coregulator. 
USP7 facilitates AR binding to AREs and activates gene transcription through 
attenuating ligand-induced ubiquitinated AR and receptor stabilization. By strictly 
controlling the dynamic USP7 association and disassociation, the AR transcriptional 
activity can be precisely fine-tuned. 
In addition, the global profiling of USP7 knockdown effect on androgen-dependent 
gene transcripts supposed the gene specific regulation manner of USP7. Given that AR-
mediated gene repression versus activation via distinct mechanisms, suggesting USP7 
may regulate AR target genes expression through multiple pathways. 
To conclude, this study biochemically identified USP7 as a novel AR coregulator which 
is required for mediation of AR transcriptional activity and specificity, thereby broadens 
the view of ubiquitin network in gene regulation. 
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Chapter 1 
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Overview 
 
The male sex hormone androgens play critical role in development and maintenance 
of male phenotype via the ligand-inducible nuclear receptor, androgen receptor (AR) to 
modulate a vast number of target genes expression. To study the mechanism of AR 
transcriptional regulation is necessary for understanding the physiological and 
pathological androgen actions. 
The AR transcriptional regulation is mediated by collaborative protein complexes 
including coregulators and specific transcription factors. Recent years the mechanisms 
of these AR transcriptional coregulators rebuild chromatin environment for gene 
transcription are well demonstrated. However, how these coregulators mediate AR post-
translational modifications and manipulate AR quantitative/ qualitative regulation are 
ill-defined. In addition, recent studies of mapping AR genome wide binding sites using 
ChIP-chip and ChIP-seq revealed the complexity of these collaborative proteins in 
androgen-dependent genes expression and broaden the view of AR transcriptional 
regulation. 
In this chapter, the physiological and pathological AR actions especially in prostate 
cancer are introduced. And the molecular mechanism of AR transcriptional regulation 
including the composition of AR transcriptional collaborative proteins as well as the 
recent studies of genome-wide AR landscape mapping in prostate cancer model cell lines 
are overviewed. Based on these research, the study aim of the thesis is emerged.  
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The physiological function of androgens 
 
1. Androgen types and synthesis 
Androgens, a kind of steroid hormone are synthesis in a series of steroidogenesis 
pathway in tesis Leydig cells. The biosynthesis of androgens in testis are under strict 
regulation via the hypothalamic-pituitary-gonadal (HPG) axis.  
Secretion of Gonadotropin-releasing hormone (GnRH) occurs in a pulsatile fashion 
from hypothalamus, and is transported to the gonadotrophs of the anterior pituitary 
gland that controls gonadotropin: follicle-stimulating hormone (FSH) and luteinizing 
hormone (LH) synthesis and secretion. In turn, LH stimulates testicular androgens 
synthesis and FSH promotes spermatogenesis, the release systemic androgen 
concentrations then feedback inhibit the signaling of LH, FSH and GnRH. The adrenal 
glands also secret androgens although it is too low to have significant physiological effect 
in male whereas in female the adrenal glands are major source of androgens (Figure 1-
1 A).  
The major circulating androgens are testosterone, in 5-reductase expressed target 
tissues such as skin and prostate, testosterone is converted to more potent metabolite 
(dihydrotestosterone) DHT before bind to receptor. In addition to testosterone and DHT, 
testis also secrets Dehydroepiandrosterone (DHEA), is primary precursor of 
estrogens1,2,3. 
 
2. The physiological function of androgens 
The male sex hormone androgens are critical for expression of male phenotype 
including sexual differentiation, development and maintenance of secondary male 
characteristics and spermatogenesis. 
The sexual phenotype formation starts from embryo stage. During embryo stage, 
androgens play essential role in sexual differentiation, male development is induced in 
the presence of testosterone and DHT, in absent of these hormones female differentiation 
occurs. Another important stage of sexual phenotype development is puberty. During 
puberty, the increased production androgens act on wide range of target tissues including 
brain, skin, muscle, bone, adipocyte and sexual organs to develop secondary male 
characteristics and spermatogenesis. Spermatogenesis is a process that spermatogonia 
or germinal cells different into spermatozoon (commonly called sperm cells) that is 
essential for preserving the number of chromosomes in the offspring and sexual 
reproduction1,2,3.  
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 The biological function of androgen receptor (AR) 
 
1. The physiological function of AR 
The varied physiology function of androgens are exerted via androgen receptor (AR), 
a 110-kD ligand-inducible nuclear receptor that expression of target genes4,5 (Figure 1-
2). Androgen receptor is expressed in wide range of tissues especially in reproductive 
system such as testis and prostate gland. Studies from AR-deficient or AR knockout 
(ARKO) male mice models revealed the central role of AR in the androgen-regulated 
reproductive development. These genetic mouse models displayed reproductive tract and 
gonadal development, as well as sexual behavior impaired phenotypes, consistent with 
the known aberrant AR target gene expression6.  
Dysregulation of AR signaling perturbs normal reproductive development and results 
in a wide range of pathological condition such as androgen-insensitive syndrome, spinal 
bulbar muscular atrophy and prostate cancer1,2,5,6. 
 
2. AR and prostate cancer 
The prostate gland is responsible for producing the fluid portion of semen and help for 
controlling the flow of urine. While the prostate functions is critically dependent on AR 
signaling, the hyperactive AR signaling modulates the expression of genes associated 
with cell cycle regulation, survival and growth that cause prostate carcinogenesis6,7,8,9,10. 
It is well accepted that AR is essential for androgen dependent prostate cancer (ADPC) 
and hormone refractory prostate cancer (HRPC) progression, however, the exact role of 
AR in prostate cancer initiation, progression and develop into hormone refractory 
prostate cancer (HRPC) remain elusive.  
Somatic AR mutation is supposed to be the major mechanism by which prostate cancer 
cells acquire the ability to survive and proliferate in the absence of androgens. In 
addition, recent studies have identified several AR splice variants that lack LBD domain, 
resulting in constitutively activated AR and may promote the progression of HRPC. 
Other hyperactive AR signaling mechanisms include AR gene amplification, alteration 
in AR coregulators expression and tumor microenvironment effects7-12.  
 
3. The gene and structure of AR 
AR is a member of the nuclear steroid receptor superfamily, member ligand-inducible 
transcription factors that mediate the expression of target genes in response to ligands 
specific to each receptor, including steroids, vitamin, thyroid hormone and xenobiotic 
agents4,5. The AR gene containing eight exons is located on the long arm of the X-
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chromosome at Xq11-12. The eight exons encode AR distinct functional motifs: the N-
terminal domain (NTD encoded by exon 1), DNA-binding domain (DBD encoded by exon2 
and 3), a hinge region (H encoded by 5’ portion of exon4), and a ligand-binding domain 
(LBD encoded by the remainder of exon4 to exon8) (Figure 1-1 B).  
A hinge region separates the DBD and the LBD, which contains a nuclear localization 
signal to facilitate ligand-dependent nuclear translocation of receptor. PEST (proline-, 
glutamate-, serine-, and threonine-rich) sequence, a degradation motif is also found in 
hinge region. The DBD contains two zinc finger motifs are contributed to DNA binding 
site recognition. The LBD is posted in C terminus and is composed of twelve-helices 
forming ligand-binding pocket. X-ray crystallographic analysis reveals that ligand 
binding induces LBD conformational change and generates a coregulators interaction 
surface. Contrary to the highly conserved DBD and LBD, the NTD is the least conserved 
region of AR contains polyglutamine and polyglycine repeats that result in variation of 
AR length. 
Like most nuclear receptors, AR possesses two transactivation domain, AF-1 and AF-
2 located in NTD and CTD respectively. The AF-1 and AF-2 domain function as docking 
sites for transcriptional coregulators recruitment and AF-1 activity is ligand 
independent whereas AF-2 activity shows ligand dependent. Although the relative 
transactivation activity of the AF-1 and the AF-2 are variable and depend on the cellular 
environment and expression of coregulators, the AF-1 and AF-2 are required for optimal 
AR transactivation4,5,6.  
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The molecular mechanism of AR transcriptional regulation  
 
In normal physiological condition, upon ligand binding the cytoplasmic AR undergoes 
conformation change results in dissociation of chaperones and reveals the NLS signal. 
The ligand-bound AR translocates to the nucleus where its binds to target gene 
regulatory regions containing DNA motif: 5’-AGAACANNNTGTTCT-3’, known as 
androgen response elements (AREs) and associates with distinct functions of 
coregulators forming a large multi-protein transcriptional complex to cooperate with 
gene regulation4,5,6,13,14 (Figure 1-2).  
Apart from general transcription factors, the composition of AR transcriptional 
complex that recruited in regulatory regions of target gene can be divided into two 
classes: coregulators and specific transcription factors that bind to their consensus 
binding elements13,14,15. 
 
1. Coregulators (Cofactors) 
In general, coregulators do not bind DNA by themselves and according to their ability 
to enhance or reduce AR transcriptional activity, coregulators can be classified into 
coactivators and corepressors. By virtue of assessing the functions by which these 
coregulators, a huge strides in the understanding of AR transcriptional regulation have 
been achieved. It is known that a large proportion of coregulators possess enzymatic 
activities and chromatin remodeling properties. 
Enzymatic properties coregulators 
Histone-modifying enzymes compose one major group of AR coregulators, they are able 
to modulate the acetylation, phosphorylation, methylation, ubiquitination and 
SUMOylation status of the local histone environment that are associated with 
transcription activation or repression. The p300/CBP and p160/SRC HATs are the best 
–characterized AR coactivators, and their expression level are correlated with androgen-
dependent prostate cancer. Even AR itself and components of the general transcriptional 
machinery as well as cooperating coregulators can be the substrates. 
Although these coregulators rebuild chromatin environment for transcriptional 
regulation is well demonstrated, the AR posttranslational modifications by these 
coregulators contribute to AR quantitative /qualitative regulation are ill-defined16,17.  
Chromatin remodeling coregulators 
  The gene transcriptional activation is associated with a series of reorganization of 
nucleosome position as well as increased accessibility of DNA for interaction with 
transcriptional machinery and integrated regulatory factors. These processes are able to 
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be accomplished by chromatin remodeling complexes. The SWI/SNF complex contains 
DNA-dependent ATPase subunit necessary for chromatin modification is one of the best 
characterized of the chromatin remodeling complexes. Activation of androgen target 
genes requires the assembly of the SWI/SNF complexes and is involved in promotion of 
prostate cancer cell proliferation13,14. 
 
2. Specific transcription factors 
A special class of transcription factor refer to pioneer factors are able to associate with 
compacted chromatin directly and modulate chromatin accessibility, thereby facilitate 
the binding of additional transcription factors. Recently, they have been implicated in 
hormone-dependent cancer including prostate cancer18,19. 
Recent studies of genome-wide AR binding sites in different stages of prostate cancer 
model cell lines have identified hundreds of androgen-regulated genes and suggested 
that the AR transcriptional program may change as the cancer progress from hormone 
dependent to hormone independent by virtue of the pioneer factor FoxA1. 
It is proposed that the development of ADPC into HRPC is accompanied the transition 
of cell-specific epigenetic marks distribution such as H3K4me1/me2. The cell-specific 
distribution of H3K4me1/me2 can recruit FoxA1, which in turn restricts the AR binding 
sites and transcription program. Hence, AR can drive distinct transcription program to 
promote ADPC and HRPC cell proliferation18,19,20. (Figure 1-3). Interestingly, the 
silencing of FoxA1 in prostate cancer cells results in reprogramming of AR binding site, 
suggesting the dual role of FoxA1 in AR transcriptional regulation21,22.  In addition to 
FoxA1, other pioneer factor, GATA2, OCT1 and ETS are also reported to regulate AR 
binding23,24.  
These studies not only alter and expand the view of these collaborative proteins in AR 
transcriptional regulation but also impress the complexity of prostate cancer. However, 
other DNA binding proteins that might be involved in modulation of AR chromatin 
binding remain to be identified.18-23 
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AR transcriptional regulation model 
 
The nuclear receptor such as ER, PR and GR undergo hormone-induced receptor 
transactivation and couple receptor proteasomal degradation. The nuclear receptor 
cyclic nature is supposed as a mechanism by which cells to fine-tuning transcription 
activation in response to rapid changes in hormone concentration.25 Unlike these nuclear 
receptors, AR is stabilized in the presence of androgens, hence cells may apply other 
mechanism to cope with the androgen response. Recent studies have proposed two 
speculations of AR transcriptional regulation model to explain the AR actions. 
 
1. Long-term sustained manner 
Androgen have been reported to stabilize AR protein, suggesting the different 
mechanism of androgen-induced AR transactivation compare to other nuclear 
receptors26,27. A study from Myles Brown’s group demonstrated that AR regulates gene 
transcription is a long term process. They investigated the time course recruitment of 
AR and coregulators such as p300 and SRC1 as well as RNA pol II to PSA gene AREs in 
LNCaP cells using ChIP. The result revealed that the AR transcriptional complexes 
accumulated on AREs continuously over 16 h and gradually declined following longer 
treatment. This scenario also coincided with the long-term PSA mRNA expression 
pattern. They also supposed that the constant elevation of AR protein level by androgen 
is the potential for secondary events of transcription28,29. 
 
2. Cyclic manner 
Contradict to long-term sustained manner, other studies demonstrated that the 
association and dissociation of AR and its coregulators is in alternative cyclic manner. It 
is assumed that nuclear receptors regulate transcription in cyclic manner that start from 
ligand binding and end in ubiquitin/proteasome-mediated degradation. As shown for 
ER, transcription initiation is a highly dynamic process of transcriptional complex 
assembly that is coupled chromatin modification and remodeling. After transition to 
elongation, the ER-transcriptional complex dissociate from regulatory elements 
through ubiquitin target receptor to degradation and allow a new round of transcription 
complex assembly and initiation30-34.  
The controversy of AR transcriptional regulation model may partly due to the intricate 
ubiquitin network in androgen signaling. Next section will simply introduce the 
ubiquitin modification system and overview the functional role of ubiquitination in AR 
transcriptional regulation.   
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The ubiquitin system in AR transcriptional regulation 
 
1. Ubiquitin system 
Ubiquitination, the covalently conjugated of 76-amino-acid polypeptide ubiquitin (Ub) 
to target protein, is a reversible posttranslational modification that provides as a tag 
either marking the labeled protein for degradation or modulates its biological function. 
  In general, ubiquitination is controlled by three step reaction initialized by E1-
mediated activation of Ub, followed by conjugation to E2 enzyme and substrate targeting 
by E3 Ub ligase. This process can be reversed by specific deubiquitinating enzymes 
(DUBs) to remove Ub from substrates or cleave the Ub linkage35 (Figure 1-4 A).  
Ub can be conjugated to target proteins either as monomer or as Ub chains that vary 
in length and linkage type. Ub chains can form through seven lysine (Lys) residues on 
its surface (Lys 6, Lys 11, Lys27, Lys 29, Lys33, Lys 48 and Lys 63). Different Ub linkages 
result in various conformations of Ub chains and create varied molecular signals. 
Whereas the role of Lys 48-linked chains in proteasome degradation and Lys 63-linked 
chains in cell signaling is well characterized, the exact function of the remaining six 
atypical Ub chains are poorly defined35,36,37.  
These vital biological functions of ubiquitination can be reversed by deubiquitination. 
Deubiquitination is mediated via DUBs which can be subdivided into five structurally 
distinct families, ubiquitin C-terminal hydrolases(UCHs), ubiquitin-specific protease 
(USPs), ovarian tumor proteases (OTUs), Josephins and JAMM/MPN+. The UCH, USP, 
OTU and Josephin families are cysteine protease, whereas the JAMM/MPN+ family 
members are zinc metalloproteases (Figure 1-4 B). DUBs can display specificity for both 
substrates and particular Ub chains, the USP DUBs are substrate- rather than Ub chain 
linkage-specific whereas JAMM family DUBs are Lys63‑specific38,39. 
 
2. The role of ubiquitination in AR transcriptional regulation 
It has become clear that androgen activates AR is accompanied AR ubiquitination, 
suggesting this modification make a contribution to AR transcriptional activation.  
Androgen-induced AR ubiquitination is accomplished by a sophisticated ubiquitin 
network40,41. Several E3 ligase has identified as AR coregulators that mediate AR 
transcriptional activity. AR is ubiquitinated by MDM2 subsequent to Akt 
phosphorylation which leads to AR degradation, hence reduces steady-state level of AR 
and attenuates AR transcriptional activity42. More recently, ChIP assay have shown that 
androgen-induced general transcription factor TFIIH phosphorylates AR and thereby 
recruits the E3 ligase: MDM2 and CHIP to AREs resulting AR polyubiquitination and 
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target receptor degradation and turnover40,43,44. Contrast to MDM2 and CHIP target 
receptor degradation, RNF6 generates Lys 6- and Lys 27-linked Ub chains that stabilize 
receptor and act as scaffold for coactivators such as ARA54 recruitment consequently 
modulate AR transcriptional activity and specificity 41,45 (Figure 1-5). 
Although less understood, deubiquitination is also involved in this ubiquitin network. 
Previous studies has shown Tumor susceptibility gene 101 (TSG101), an E2-like enzyme 
deprived of ubiquitin conjugase activity, transiently locks AR in monoubiquitinated state 
by preventing polyubiquitination, thus extends AR-mediated transcription46. In addition, 
the DUBs USP26 have been proposed to counteract hormone-induced AR ubiquitination 
by MDM2 and prolong AR transcriptional activity47. 
  Even though the androgen-mediated intricate AR ubiquitination that contribute to 
distinct cell signals are essential for AR transcriptional regulation. The mechanism of 
manipulating this ubiquitin network including E3 ligase and DUBs and fine-tuning AR 
transcriptional activity is remain elusive.    
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Study purpose 
 
The male sex hormone androgens are critical for expression and maintenance of male 
phenotype. The extensive physiological function of androgens are mainly exerted by the 
ligand-inducible nuclear receptor, AR to mediate a vast number of target gene expression. 
Hence, aberrant AR signaling is implicated in a wide range of disease including prostate 
cancer. To understand the comprehensive molecular mechanism of AR transcriptional 
regulation is essential for elucidating the physiological and pathological role of 
androgens.  
Studies gained from prostate cancer model cell lines revealed that the AR-mediated 
transcription is a highly regulated and complex process. Prior to ligand stimulation, the 
pioneer factors are recruited to the cell-specific distribution epigenetic marks and 
establish the cell-specific AR binding patterns. Upon androgen stimulation or other 
signaling that activate AR, AR binds to AREs that created by pioneer factors and recruits 
coregulators forming a huge complex to activate transcription.  
The composition of these AR transcriptional complexes existed on AREs are temporal, 
quantitative variation and gene specific. They rebuild the chromatin environment and 
modulate AR or components of these complexes post-translational modifications to affect 
gene transcription. Hence, to unravel the composition of these AR transcriptional 
complexes and investigate how they manipulate AR quantitative /qualitative regulation 
as well as mediate target gene expression is an efficient strategy to understand the AR 
transcriptional regulation. 
The aim of this study is to reveal a novel AR transcriptional regulation mechanism by 
identifying AR coregulators. For this purpose I biochemical purification of the AR-
associated proteins in prostate cancer cells, and investigate the mechanism by which 
these coregulators regulate AR quantitative /qualitative regulation as well as identify 
their specific target gene using the genome-wide transcript profiling method. Through 
this integrate investigation, the comprehensive AR transcriptional regulation by these 
coregulators that identified can be deciphered (Figure 1-6). 
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Figure 1-1 The androgens biosynthesis pathway and the structure domain 
of AR 
(A) The biosynthesis of androgens is via hypothalamic-pituitary-gonadal (HPG)  
axis. The synthesized testosterone then feedback inhibit GnRH and LH secretion, 
making the system comes full circle. FSH is not shown in this diagram. (B) AR is a 
member of the nuclear steroid receptor superfamily. The AR protein comprises distinct 
functional domains and are encoded by eight exons. 
(A) 
(B) 
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Figure 1-2 The androgen actions are exerted via androgen receptor (AR) 
The circulating testosterone directly penetrates across cell membrane of target 
cells, in 5-reductase express tissues such as prostate glands, testosterone is 
converted to DHT by 5-reductase before binding to AR. The liganded AR dissociates 
with Hsp proteins and translocates to nucleus where it binds to AREs and recruits a 
series of coregulators that exhibit distinct functions to regulate a vast number of 
target gene transcription and output into androgen actions. 
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Figure 1-3 AR regulates cell-specific transcription program to promote 
prostate cancer cell proliferation 
It is supposed that AR can drive distinct transcription program in ADPC and HRPC 
cells. In ADPC, AR promotes cell proliferation by expression of G1/S phase transition 
genes. Contrast to this, HRPC cell proliferation is mediated by expression of M phase 
cell cycle genes. 
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Figure 1-4 The ubiquitination chain formation and hydrolysis 
(A) The ubiquitination is mediated by three step enzymatic cascades, and the  
ubiquitin chain can be reversed by DUBs. (B) The DUBs can be subdivided into five 
structurally distinct families according to their catalytic domains. The UCH, USP, 
OTU and Josephin families are cysteine proteases, whereas the JAMM/MPN+ family 
members are zinc metalloproteases 
 
 
 
 
 
(A) 
(B) 
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Figure 1-5 The role of ubiquitination in AR transcriptional activity 
regulation 
The androgen-regulated AR ubiquitination including MDM2 and CHIP generate 
Ub chain that target receptor degradation as well as RNF6 generates K-6 and K-27 
Ub chain that stabilize receptor and coactivators recruitment. 
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Figure 1-6 Study purpose 
The aim of this study is to reveal a novel AR transcriptional regulation mechanism 
by identifying AR coregulators. For this purpose the endogenous AR-associated 
proteins in prostate cancer cells are purified using antibody affinity purification. The 
interested coregulator candidates are focused. And the AR quantitative/qualitative 
regulation as well as the cell transcriptome profiling that modulate by these 
coregulators are investigated. 
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Chapter 2  
Identification of AR transcriptional coregulators in 
prostate cancer cells 
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Overview 
 
Unraveling the composition of AR transcriptional complexes and investigate their 
functional role in AR quantitative /qualitative regulation is an efficient strategy to revel 
novel AR transcriptional regulation mechanism and understand the physiological and 
pathological AR action.  
To identify the endogenous AR-associated proteins in prostate cancer cells, the anti- 
AR antibody affinity purification was performed. Among these AR coregulator 
candidates, the potential candidates that might modulate AR post-translational 
modifications were focused and further investigated their function in AR quantitative 
/qualitative regulation. 
Through the biochemical method to identify the endogenous AR-associated proteins in 
prostate cancer cells and further examine their functional role in AR transcriptional 
regulation, I hope to discover a novel AR- target gene regulation mechanism. 
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Material and method 
 
1. Material 
1. Plasmid 
Flag-USP7   
USP7 cDNA fragments were generated by polymerase chain reaction (PCR) and were 
subcloned into flag-pcIneo vector (Invitrogen, Grand Island, NY) at the Xho I and 
SmaI sites. The forward and reverse primers were  
5´-CGGGATCCATGGCGGCGACTACTG-3´and 
5´-CGGATATCTTCTGAAAAGGGGGGAAAC -3´, respectively.  
HA-MDM2 
Human MDM2 cDNA fragments were generated by polymerase chain reaction (PCR) 
and were subcloned into HA-pcIneo vector (Invitrogen, Grand Island, NY) at the XhoI    
and SmaI sites. The forward and reverse primers were  
5´- GGAACTCGAGATGGTGAGGAGCAGGCAAAT -3´and 
5´- GGAACCCGGGCTAGGGGAAATAAGTTAGCACAATC -3´, respectively.  
wt-AR  
The wt-AR plasmid were kindly provided by Dr. Suzuki.  
These vectors sequence were confirmed by DNA sequencing. 
2. Antibody 
➀ Immunoblotting 
Primary antibodies 
AR (N20): Santa Cruz Biotechnology (sc-816) 1: 3000 dilution 
USP7: Abcam (ab4080) 1: 3000 dilution 
MDM2 (SPM14): Santa Cruz Biotechnology (sc-965) 1:1000 dilution 
Ubiquitin(P4D1): Santa Cruz Biotechnology(sc-8017 )1:1000 dilution 
Flag-M2: Sigma-Aldrich (F3165) 1:5000 dilution 
-Tubulin: Sigma-Aldrich (T6074) 1: 5000 dilution 
-Actin: Abcam (ab8224) 1: 5000 dilution 
Secondary antibodies 
Rabbit: Rabbit IgG HRP (Jackson Immuno research) 
Mouse: Mouse IgG HRP (Jackson Immuno research) 
② Immunoprecipitation 
AR (441): Santa Cruz Biotechnology (sc-7305) 1: 1000 dilution 
USP7: Bethyl Laboratory. (A300-033A) 1: 1000 dilution 
Flag-M2 agarose: Sigma-Aldrich 
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3. Reagent 
➀  Androgen: 5-dihydrotestosterone (DHT) ; Sigma-Aldrich, was dissolved in 
ethanol to make 10-3, 10-5 M for stock and diluted to 10-8 M prior to use. 
② Protease inhibiton: MG132 ; PEPTIDE (3175-v) was dissolved in DMSO to make 
10 mM for stock. 
2. Method 
1. Cell culture 
LNCaP and 22Rv1 cells were grown at 37 ℃ under 5% CO2 in 10-cm plastic dishes 
containing 10 ml of RPMI 1640 media with 10% fetal bovine serum, 0.2 mM L-glutamine, 
100 U/ml penicillin, 100 μg/ml streptomycin. HEK 293T cells were cultured in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 0.2 mM L-glutamine, 100 U/ml 
penicillin, 100 ug/ml streptomycin. Before DHT treatment, cells were incubated in 
phenol-red free medium with 5% charcoal-stripped FBS (CCS) for 3 days. 
2. Anti-AR antibody affinity protein purification 
➀ Preparation of anti-AR antibody-conjugated column 
Material 
 BC100 buffer: 20 mM HEPES pH7.6, 10% glycerol, 100 mM KCl, 0.2 mM EDTA 
 0.2 M triethanolamine pH8.2 
 DMP: dimethylpimelimidate (PIERCE) 
 0.1 M glycine-HCl pH 2.0 
 50 mM Tris pH 8.0 
 Protein G dynabeads 
Procedure  
Coupling antibody with dynabeads protein G 
100 μg AR and mouse IgG antibodies were diluted to final concentration 0.1 μg/μl 
using BC100, respectively. The dynabeads protein G slurry 200 ul was washed twice 
using BC100 prior to couple with antibody dilution, mixed well and rotated overnight 
at 4 ℃.  
Crosslinking 
The beads after coupling was washed using BC100, followed by 0.2 M 
triethanolamine (pH 8.2) washed. DMP is unstable in aqueous solution, should be 
prepared immediately prior use. Hence, to crosslinking Ab to beads, fresh prepared 
20 mM DPM/ triethanolamine solution was added and rotated at room temperature 
(RT) for 1 h. 50 mM Tris-HCl (pH7.5) was added and rotated at RT for 15 min to stop 
crosslinking reaction and washed using BC100 three times. To remove the free 
antibodies that were not crosslinking to beads, 0.1 M glycine-HCl (pH 2.0) was added 
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and removed immediately. 50 mM Tris-HCl (pH 8.0) was used for neutralization.    
After washed by BC100 three times, 400 ul of BC100 was added. For storage, added 
0.01% NaN3 to beads-Ab solution and stored at 4 ℃. 
Validation of crosslinking efficiency 
To check the crosslinking efficiency, sampled beads before and after crosslinking. 
Meanwhile, to check the efficiency of antibody couple with beads, sampled the diluted 
Ab solution before coupling and the supernatant after coupling. The SDS loading 
buffer was added to these samples and boiled at 95 ℃ for 5min. After centrifuged, 
the supernatant were subjected to SDS-PAGE and visualized using silver staining. 
Before crosslinking, the IgG heavy chain (55 kD) and IgG light chain (25 kD) bands 
are exhibited in silver staining. After crosslinking, the two bands are unable to be 
observed. According to this, the crosslinking efficiency can be evaluated.  
② Extraction of cell lysate 
Material 
 TNE buffer: 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.5% NP-40 
Procedure 
1×108 cells 22Rv1 cells maintained in 10 cm dish (10 cm dish, 40 plates) were 
treated with 10 nM DHT for 6 h and harvested using TNE buffer (add protease 
inhibitor cocktail (Roche), 1 mM Na3VO4, 2 mM NaF, 1 mM PMSF prior to use). The 
lysate were filtered through 0.22 um filter and the protein concentrations were 
measured using BCA protein assay.  
③ Purification of AR-associated proteins using anti-AR antibody-conjugated column 
Material 
 0.05%TFA (Trifluoroacetic acid) 
 TCA (Trichloroacetic acid) 
 Acetone (Keep at 4 ℃ prior to use) 
Procedure 
Immunoprecipitation 
The cell lysate from② were divided to two part and contacted with AR and IgG 
antibody-conjugated beads gained from➀ , mixed well and rotated at 4 ℃  for 
overnight. The supernatant was discarded and beads were washed several times 
using TNE buffer. To elute the proteins that associated with beads, added 0.05% TFA 
and incubated at RT for 15 min. The eluate was transferred to new tube, and repeated 
this procedure again. The twice eluate were combined and subjected to TCA 
precipitation.    
TCA precipitation 
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For TCA precipitation, the 1 volume of 100% TCA was added to 9 volumes of protein  
sample, vortex well and incubated at 4 ℃ for 30 min. After centrifuged, discarded 
supernatant and washed the pellet using cold acetone, repeated twice. Dried pellet 
until acetone totally evaporated. For silver staining and immunoblotting, added SDS 
loading buffer, boiled at 95 ℃  for 5 min. If needed, add Tris-HCl (pH 8.8) to 
neutralize the solution. The sample were visualized by silver staining and excised for 
LC-MS/MS identification. 
Silver staining 
The SDS loading buffer mixture sample were subjected to SDS-PAGE 
electrophoresis using 2-15% gradient gel: MULTIGEL II Mini 2/15 13W (Cosmo Bio, 
DCB-414855). Proteins that separated in the gel was visualized by silver staining. 
Silver staining was carried out using SilverQuest™ Silver Staining Kit (Invitrogen, 
LC6070) according to the manufacturer’s instructions. 
④ Gel digestion for LC-MS-MS Analysis 
Material 
(All prepare prior to use) 
 Reduction buffer: 10 mM DTT in 100 mM NH4HCO3 
 Alkylation buffer: 55 mM iodoacetamide in 100 mM NH4HCO3 
 Trypsin buffer: 3-25 ng/ml Trypsin (Trypsin Gold-Mass Spec Grade, Promega) in 50 
mM NH4HCO3 
 Extraction buffer: 5% formic acid in 50% acetonitrile 
Procedure 
The gels from silver staining were placed on a clean glass and rinsed with MQ. The 
bands of interest were excised and the same molecular weight site of IgG gel were 
also excised for negative control respectively. The gel slices were destained in 50% 
acetonitrile in 100 mM NH4HCO3, lyophilized and rehydrated in 50 ul of 10 mM DTT 
in 100 mM NH4HCO3. After incubated at 56 ℃ for 1 h, the DTT supernatant was 
removed and 50 ul of 55 mM iodoacetamide solution was added and incubated in dark 
for 45 min. The supernatant was discarded and the gel slices were lyophilized and 
digested with trypsin at 37 ℃ for overnight. The tryptic peptides were extracted 
from gel slices using 5% formic acid in 50% acetonitrile. This solution was lyophilized 
and the peptides reconstituted in 0.1% formic acid prior to LC-MS/MS analysis. 
3. Transfection of cells with plasmids 
Transient transfection of cells with plasmids was performed with X-tremeGENE HP 
DNA Transfection Reagent (Roche) according to the manufacturer's instructions but with 
slight modifications.    
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4. Immunoblotting and Immunoprecipitation 
For immunoblotting, cell lysates were collected using TNE lysis buffer ( 50 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.5% NP-40, cOmplete protease inhibitor 
cocktail (Roche), 1 mM Na3VO4, 2 mM NaF, 1 mM PMSF and 10 mM N-ethylmaleimide 
NEM). For immunoblotting analyses, cell lysates were separated on 7-15% sodium 
dodecyl sulfate-polyacrylamide (SDS) gel, and then proteins in the SDS gels were 
transferred to a polyvinylidene difluoride membrane. The membrane were blocked with 
3% skim milk in PBST and incubated with primary antibodies overnight at 4 ℃. After 
wash with PBST three times, the membrane with primary antibodies was incubated with 
horseradish peroxidase-conjugated secondary antibodies for 1 h at RT. Immunoreactive 
signals were detected with Luminata Western HRP Substrates (Millipore). 
For immunoprecipitation, antibodies were added to lysate and incubated at 4 ℃ for 
16 h. The immunocomplexes were collected using protein G dynabeads and the beads 
were washed with TNE buffer five times and visualized by immunoblotting. 
For detecting ubiquitinated proteins, immunoprecipitation was performed under 
denaturing condition. The lysate were added with SDS to a concentration 1% , and then 
heated at 95 ℃ for 10 min. The lysates were diluted using TNE buffer to reduced SDS 
concentration and incubated at 4 ℃ for 30 min before antibody was added. 
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Result 
 
1. Identification of the AR-associated proteins using antibody affinity 
purification 
To identify the novel AR coregulators, the endogenous AR-associated proteins in 22Rv1 
cells were purified using AR antibody-conjugated column. The HRPC 22Rv1 cells are 
derived from human prostatic carcinoma xenograft CWR22R, and widely utilized for 
HRPC study47. It is known that 22Rv1 cells not only express exon3 duplication (code for 
zinc finger) full-length AR protein but also exhibit 77-kD AR variants. This AR variants 
lack CTD domain (including ligand binding domain) of AR and are suggested to exert 
critical function in HRPC progression49. 
The cell lysate from DHT-treated 22Rv1 were incubated with AR antibody-conjugated 
column, the proteins that associated with antibody were eluated using acids and 
subjected to TCA precipitation subsequently (Figure 2-1 A). The protein in the extracts 
were visualized by silver staining, and the specific bands were excised and subjected to 
LC-MS/MS identification (Figure 2-1 B). Several proteins were identified as AR 
coregulator candidates including the known AR coregulator histone-arginine N-
methyltransferase (PRMT5) 
  Among these candidates, the molecular weight 126-kD protein band was identified as 
ubiquitin specific peptidase 7 (USP7), which FDR<1%, peptides number＞10, score on 
the list top1 showing the high confidence.  
USP7 belongs to USP family DUBs that possesses a wide range of substrates including 
the tumor suppressor protein P53 and its regulator murine double minute (MDM2) as 
well as the transcription factors FOXO450,51,52(Figure 2-2). By virtue of the 
deubiquitinase activity, USP7 is able to enhance the target protein stability or alter 
subcellular localization. Additionally, USP7 was reported overexpression in prostate 
cancer cells53. It is supposed that aberrant expression of coregulators contribute to 
hyperactive AR signaling and associate with prostate cancer progression, suggesting 
USP7 may exert important role in AR transcriptional regulation.  
 
2. USP7 is involved in androgen-regulated AR ubiquitination 
Although several E3 ligases have been identified as AR coregulators, the 
understanding of DUBs in AR transcriptional regulation is few and far between. Thus, 
USP7 was focused and further investigated its functional role in androgen-dependent 
gene expression. 
The interaction between USP7 and AR was validated in AR and USP7 overexpression 
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293T cells using immunoprecipitation (Figure 2-3 A). The endogenous interaction was 
also confirmed in prostate cancer cell lines LNCaP and 22Rv1 upon DHT treatment 
(Figure 2-3 B). These results indicated that the interaction between USP7 and AR was 
androgen-dependent enhanced, implying USP7 is involved in androgen actions. 
It was proposed that the ubiquitinated AR generated by androgen is important for AR 
transcriptional activity. The DUBs USP7 might participate in the ubiquitin network and 
regulate AR transcriptional activity. To corroborate this speculation, the time course of 
AR ubiquitination upon DHT stimulation in LNCaP cells was examined. Consistent with 
previous report, the result demonstrated that the ubiquitinated AR was accumulated 
upon androgens treatment time course (Figure 2-4 A). In addition, the ubiquitinated AR 
generated by DHT was abolished by overexpression of USP7. And the AR E3 ligase, 
MDM2 was used as positive control of this in vivo ubiquitination assay (Figure 2-4 B). 
Whether USP7 is an AR deubiquitinase need to be further investigated by in vitro 
ubiquitination assay.  
  The result demonstrated that USP7 is a novel AR-associated protein and is involved 
in AR ubiquitination regulation. 
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Summary 
  
To revel a novel AR transcriptional regulation mechanism by unraveling the 
composition of AR transcriptional complexes in prostate cancer cells. The anti-AR 
antibody affinity purification was applied, and several AR coregulator candidates were 
identified. 
USP7 was focused for further investigation due to its highly identified score and the 
elusive role of DUBs in AR transcriptional regulation. The endogenous interaction 
between USP7 and AR was validated, confirming the confidence and reliable of the 
identification result. 
Given that the androgen-produced ubiquitinated AR implicates in AR transactivation, 
the effect of USP7 on AR ubiquitination was investigated. The result indicated that 
USP7 abolished androgen-generated ubiquitinated AR, while whether AR is a substrate 
of USP7 need to be further verified.  
It is supposed that the ubiquitinated AR implicated in coactivators recruitment and 
transactivation coupled-proteasomal degradation. As a result, USP7 deubiquitinates AR 
may oppose these outcomes of AR ubiquitination, and is involved in AR transcriptional 
regulation. 
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Figure 2-1 The identification of AR-associated proteins in prostate cancer 
cells using antibody affinity purification 
(A) The scheme of antibody affinity protein purification (B) The sample from  
scheme (A) were visualized through silver staining. These specific bands were excised 
and subjected to LC-MS/MS identification subsequently.  
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Figure 2-2 USP7 is a deubiquitinating enzyme (DUBs) 
(A) The structure domain of USP7. USP7 belongs to USP family DUBs, and 
comprises TRAF domain that contributes substrates interaction and catalytic domain 
as well as five UBL domain. (B) The regulator role of USP7 in P53 and FOXO 
transcription factor. The DUBs USP7 is involved in P53 protein stability and FOXO 
subcellular location mediation through removing ubiquitin from substrates. 
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Figure 2-3 Validation of the interaction between AR and USP7 
(A) 293T cells were transfected with Flag-USP7 and wt-AR expression vectors for 
48 h and followed by 10 nM DHT incubation for 4 h before cells were harvested. 
Immunoprecipitation assay was adopted using anti-Flag M2 agarose. (B) The 
endogenous interaction of USP7 and AR was DHT-dependent enhanced in LNCaP 
and 22Rv1 cells by reciprocal coimmunoprecipitation assays using antibodies as 
indicated. 
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Figure 2-4 The DHT-generated polyubiquitinated AR is abolished by USP7 
(A) DHT induced AR polyubiquitination in LNCaP cells. (B) USP7 attenuated  
ubiquitinated AR generated by DHT. LNCaP cells that treated with 10 nM DHT as 
indicated time periods (A) or transfected with plasmid as indicated (B) were harvested 
and subjected to immunoprecipitation using AR antibody under denature condition. 
The AR E3 ligase MDM2 was utilized as positive control in (B) 
 
 
(A) (B) 
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Chapter 3  
The elucidation of USP7 functional role in AR 
transcriptional regulation 
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Overview 
   
To reveal a novel AR transcriptional regulation mechanism, the endogenous AR-
associated proteins were biochemically purified and the DUBs USP7 was identified as a 
novel AR-associated protein that is involved in androgen-regulated AR ubiquitination.  
In this chapter the mechanism by which USP7 modulates AR quantitative/ qualitative 
regulation and affects target gene expression were further investigated. Given that 
USP7 is indicated mostly localized in nucleus, the study of USP7 in AR transcriptional 
regulation was focused on chromatin region. The dynamic USP7 recruitment to AREs 
was observed using ChIP-qPCR. 
In addition, to decipher the exhaustive regulation profile by which USP7 in androgen-
dependent gene expression, the RNA-seq analysis was adopted in USP7 knockdown 
LNCaP cells. Finally, the mechanism of USP7 modulates quantitative/ qualitative AR 
was clarified.  
Through the integrated analysis of genome-wide transcripts profiling and the AR 
quantitative/qualitative regulation, the comprehensive mechanism of AR transcriptional 
regulation by USP7 was emerged.  
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Material and method 
 
1. Material 
1. Plasmid 
ARE-Tk-Luciferase reporter  
The ARE-Tk-Luc reporter plasmid was kindly provided by Dr. Suzuki. 
2. siRNA 
USP7 siRNA 
158  
GAGCUUUGUCGAGUGUUGCUCGAUA 
UAUCGAGCAACACUCGACAAAGCUC 
159 
GGGAUGGCAAAUGGUGUAAAUUUGA 
UCAAAUUUACACCAUUUGCCAUCCC 
160 
CCGGGACCUGUUAGAAGAAUGUAAA 
UUUACAUUCUUCUAACAGGUCCCGG 
3. Antibody 
➀ Chromatin immunoprecipitation 
AR (441): Santa Cruz Biotechnology (sc-7305) 1: 1000 dilution 
USP7: Bethyl Laboratory. (A300-033A) 1: 1000 dilution 
4. Reagent 
➀ USP7 inhibitor : P22077 ; TOCRIS (4485) was dissolved in DMSO to make 20 mM 
for stock 
② Cycloheximide: Sigma was dissolved in DMSO to make 50 mg/ml for stock 
 
2. Method 
1. Chromatin immunoprecipitation and quantitative PCR 
 LNCaP were crosslinked with 1% formaldehyde for 10 min, quenched with 125 mM 
glycine and then sonicated. Solube chromatin was immunoprecipitated using AR, USP7 
and control antibodies that crosslinked with protein A dynabeads (Dynal) overnight at 
4 ℃. After this, beads were wash several times and eluted with elution buffer ( 50 mM 
Tris-HCl, 10 mM EDTA and 1% SDS) for 20 min at 65℃. The eluates were incubated at 
65 ℃ overnight to reverse crosslinks and then treated with RNaseA and followed by 
proteinase K. The samples were purified using PCR purification kit (Qiagen). 
Quantitative PCR was performed using KAPA SYBR Fast qPCR kit (Kapa Biosystems) 
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on an ABI 7500 PCR system (Applied Biosystems).  
As for Re ChIP, the first-round antibody-crosslinked beads was added to chromatin 
extracts and incubated overnight at 4 ℃. The bounded protein complexes were eluted 
by 10 mM DTT at 37 ℃ for 30 min, and the elution was then diluted ten times and 
subsequently reimmunoprecipitated by second-round or control IgG antibodies overnight 
at 4 ℃. The results were presented as fold-enrichment over control ChIP or as the 
percentage of input chromatin that was precipitated. Primers used in this study were 
listed： 
FKBP5  
5´- CTTCACGCCTGTGTTGCTTTTA-3´and 
5´-AGGGTGCAGGACGTTCCA-3´ 
PDE9A (B41) 
5´- GCCTCCCCCGTGCAG-3´and 
5´-TGCAAGGCACGTCTCAATTC -3´ 
PSA (AREIII) 
5´- TGGGACAACTTGCAAACCTG-3´and 
5´- CCAGAGTAGGTCTGTTTTCAATCCA -3´ 
TMPRSS2 (AREV) 
5´- TGGTCCTGGATGATAAAAAAAGTTT-3´and 
5´- GACATACGCCCCACAACAGA-3´ 
FKBP5-Ctril 
5´- CTCTTTCAACTGAGGCCTGG-3´and 
5´- CTCCCAAAGTGCTGGGATTA-3´ 
PSA-Ctril 
5´- TAGCTGGGACTACAGGCACC-3´and 
5´- TAATCCCAGCACTTTGGGAG-3´ 
2. RNA isolation and RT-PCR  
Total RNA was isolated using Trizol (Invitrogen) and Nucleospin RNA II (Macherey-
Nagel) following the manufacturer’s instruction. Synthesis of complementary DNA was 
performed using ReverTra qPCR RT Master Mix (TOYOBO). cDNA was amplified with 
KAPA SYBR fast qPCR kit (Kapa Biosystem) on an ABI 7500 real time PCR system 
(Applied Biosystem). Primer sequences are listed: 
BMF 
5´-GAGGTACAGATTGCCCGAAA-3´ 
5´-TTCAAAGCAAGGTTGTGCAG-3´ 
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CDC6 
5´-ACCTATGCAACACTCCCCATT-3´ 
5´-TGGCTAGTTCTCTTTTGCTAGGA-3´ 
CLDN8 
5´-CGGCTGGAATCATCTTCATCA-3´ 
5´-TTGGCAACCCAGCTCACAG-3´ 
E2F1 
5´-TCCAAGAACCACATCCAGTG-3´ 
5´-CTGGGTCAACCCCTCAAG-3´ 
FKBP5  
5´-GCGGAGAGTGACGGAGTC-3´ 
5´-TGGGGCTTTCTTCATTGTTC-3´ 
HES6 
5´-AGCCCCTGGTGGAGAAGA -3´ 
5´-CAGCACTTCGGCGTTCTC -3´ 
NRDG1 
5´-GTGGAGAAAGGGGAGACCAT-3´ 
5´-ACAGCGTGACGTGAACAGAG-3´   
PDE9A 
5´-GATCCCAATGTTTGAAACAGTGAC-3´ 
5´-TCCCAAAGTGGCTGCAGC-3´ 
PSA 
5´-TGTGTGCTGGACGCTGGA-3´ 
5´-CACTGCCCCATGACGTGAT-3´ 
SLC44A1 
5´-TTTCCTGCTATGCCAAGTTTGC -3´ 
5´-CCAGAATCGTTAAGATCCACACA -3´ 
SLC45A3 
5´-GGCCCGGAGACACTATGAT -3´ 
5´-CCATGACCAGAGAGAAGACCA -3´ 
TMPRSS2  
5´-GGACAGTGTGCACCTCAAAGAC-3´ 
5´-TCCCACGAGGAAGGTCCC-3´ 
UTG2B15 
5´-GTG TTG GGAATA TTATGACTACAGTAA C -3´ 
5´-GGGTATGTT AAATAGTTCAGCCAGT -3´ 
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UTG2B17 
5´-TGA CTT TTGGTTTCAAGC ATA -3´ 
5´-TTCCATTTCCTTAGGCAAGGG -3´ 
3. RNA-Seq analysis. 
After transfection with USP7 siRNA for 72 h, LNCaP cells were exposed to 10 nM DHT 
or vehicle for 16 h and harvested for RNA-seq analysis. Total RNA was isolated using  
Trizol (Invitrogen) and Nucleospin RNA II (Macherey-Nagel) following the 
manufacturer’s instruction. One microgram of mRNA was used for library preparation 
using Illumina TruSeq RNA sample Preparation v2 kit (TruSeq) according to the 
manufacturer's instructions, followed by sequencing on the Illumina HiSeq2500 
platform. The data graphic were made by R. (http://www.R-project.org.) Gene Ontology 
(GO) analysis was performed using the web tool Database for Annotation, Visualization 
and Integrated Discovery (DAVID) (http://david.abcc.ncifcrf.gov/) 
4. Cell proliferation assay 
LNCaP cells maintained in 10 cm dish were transfected with USP7 siRNA for 24 h 
before cells were seeded in 12 well plate at a density of 6×104 cells/well, and incubated 
in RPMI 1640 (phenol-red free medium) containing 5 % charcoal stripped FBS (As 0 h). 
The cell number was counted using Neubauer Chamber at 48 h and 96 h. 
5. Luciferase assay 
The reporter assay is performed using Dual-luciferase Reporter assay system 
(Promega). The cells maintained in 10 cm dish were seed in 12 well plate for 18 h and 
co-transfected with ARE-tk-containing luciferase reporter (100 ng/well) and wt-AR (20 
ng/well) and flag-USP7 (50 ng/well) expression vectors for 24 h. The cell were harvested 
and subjected to luciferase assay following the manufacturer’s instruction. 
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Result 
 
1. USP7 associates with AR on AREs upon rapid DHT stimulation 
Given that USP7 is proposed mainly localized in nucleus, the investigation was 
focused on chromatin region. To observe the time course of USP7 recruitment to AREs, 
the chromatin immunoprecipitation with qPCR assay was performed in DHT-treated 
LNCaP cells. Considering the long-term sustained model, supposing that AR 
recruitment to AREs parallels with coactivators such as p300 and SRC1 over 16 h. The 
observation of the AR and USP7 recruitment to the well characterized AR-target genes: 
PSA, PDE9A and FKBP5 gene AREs was at DHT stimulation 0, 1, 4 and 16 h. 
The recruitment of AR to AREs were gradually increased after DHT treatment and 
the accumulation was maintained until 16 h although with decline (Figure 3-1 A). 
Contrast to AR, the recruitment of USP7 reached the summit upon DHT treatment 1 h 
or may be earlier and declined rapidly, suggesting the short duration of USP7 associated 
with AR on chromatin (Figure 3-1 B). 
To further confirm the association of USP7 and AR on AREs, Re ChIP assay was 
adopted in DHT-stimulated for 1 h LNCaP cells. As shown in Figure 3-2, the association 
of USP7 and AR on FKBP5 and PSA gene AREs was enhanced upon DHT stimulation.  
  Together, these results exhibited that USP7 and AR form complex on AREs upon short-
term DHT stimulation and suggested that USP7 may participate in AR transcriptional 
activation early stage. 
 
2. The recruitment of USP7 to AREs is AR dependent 
Since USP7 associated with AR on AREs upon DHT treatment, to examine the binding 
of USP7 to AREs is dependent on AR or not, the pure AR antagonist bicalutamide was 
used. Bicalutamide inhibits receptor activation and chromatin recruitment by 
preventing the binding of endogenous androgens to AR. 
LNCaP cells were pretreated with bicalutamide and followed by DHT stimulation, the 
DNA bound USP7 and AR was examined by ChIP-qPCR assay. The inhibition effect of 
bicalutamide on AR chromatin recruitment was confirmed in Figure 3-3. Parallel with 
AR, the DHT-enhanced recruitment of USP7 to PSA, PDE9A and FKBP5 gene AREs 
were diminished (Figure 3-4). This result indicated the AR-dependently recruitment of 
USP7 to AREs. 
 
3. USP7 is involved in androgen-dependent gene transcription 
The previous data revealed that USP7 and AR form complex on AREs is in ligand 
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dependent manner, suggesting USP7 may cooperate with AR to regulate target gene 
transcription.  
To corroborate this speculation, the effect of USP7 overexpression on ARE-containing 
luciferase reporter activity was investigated. The result revealed that the DHT-induced 
ARE-containing reporter activity was inhibited by overexpression of USP7 in 293T and 
22Rv1 cells (Figure 3-5 A). Consistent with this result, USP7 knockdown activated the 
ARE-containing reporter activity (Figure 3-5 B), showing the corepressor role of USP7 
in AR-dependent gene transcription. 
To further examine the role of USP7 in androgen-dependent genes transcription, I 
observed the effect of P22077, a recently identified small-molecule USP7 inhibitor on 
DHT-stimulated the known androgen inducible genes mRNA expression in LNCaP cells53. 
The time course of several AR-target genes mRNA expression stimulated by 10 nM DHT 
in LNCaP cells was validated, and 8 h was chosen for the subsequent analysis (Figure 
3-6). Contradict to the data that USP7 trans-repressed ARE-reporter activity, P22077 
dose dependently inhibited the DHT-stimulated expression of PSA and FKBP5 mRNA 
(Figure 3-7). 
Due to the reporter assay cannot reliably reflect the AREs chromatin environment 
within cells, the controversial effect of USP7 on ARE-reporter activity and androgen-
inducible gene mRNA expression suggested the epigenetic enzymes network and the 
cross-talk between the AREs chromatin specific marks are critical for USP7 function. 
  Together, the contradictive results revealed that USP7 is involved in androgen-
dependent gene transcription and may mediate AR transcriptional regulation through 
multiple pathways.  
 
4. USP7 specificity regulates a subset of androgen-dependent genes  
Recent evidences supported that many AR coregulators function in gene-specific 
manner, such as RNF6 specificity affects a subset of AR target gene41. Additionally, the 
contradictive effect of USP7 on ARE-reporter activity and DHT-induced gene mRNA 
expression suggested that USP7 might exert diverse functions on AR-target gene 
regulation. Hence, to gain the comprehensive profile of USP7 in AR transcriptional 
regulation, and identify the USP7-dependent genes, the effect of USP7 knockdown on 
LNCaP cells transcriptome profiling was analyzed using RNA-sequencing (RNA-seq). 
Three different USP7 specific siRNA oligonucleotides were used to knock down USP7 
in LNCaP prostate cancer cells and the protein expression was examined by 
immunoblotting (Figure 3-8 A). The effect of the three USP7 siRNA on PSA mRNA 
expression was confirmed by qPCR. Consistent with the effect of USP7 inhibitor P22077, 
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DHT-stimulated PSA mRNA expression was attenuated in three USP7 siRNA 
transfected cells (Figure 3-8 B). The oligonucleotide 160 was used for subsequent RNA-
seq analysis.      
The expression of USP7 in LNCaP prostate cancer cells was knockdown by siRNA and 
treated with 10 nM DHT for 16 h in hormone starvation condition before RNA extraction. 
The isolated RNA were subjected to RNA-seq to prolife the transcriptome (Figure 3-9 A) 
and protein expression including USP7 and PSA were examined using immunoblotting 
(Figure 3-9 B).  
Total 11460 transcripts were mapped and quantified by RNA-seq and their 
quantitative result were visualized using heatmap (Figure 3-10). Knockdown of USP7 
resulted in profound global gene transcripts variations in DHT-treated cells. Androgen-
response genes in LNCaP cells are mainly regulated by AR, suggesting the importance 
of USP7 in AR transcriptional regulation. In addition, several know AR target genes 
were filtered and visualized using heatmap. Among DHT-activated genes, knockdown of 
USP7 had significant effect on a subset of gene expression, including FAM111B, KLK2, 
KLK3, FKBP5, E2F1, MCM2, 4, 6, 7 and CDC6. Meanwhile, USP7 knockdown appeared 
to have little or no effect on another subset of AR target genes including TMPRSS2, 
SLC45A3, PMEPA1 and CLDN8. On the other hand, among DHT-repressed genes, 
knockdown of USP7 derepressed BMF, CXCR7 and TRPC4 but was without significant 
effect on UTG2B15 and UTG2B17 (Figure 3-11). The result revealed that USP7 
specifically regulates a subset of androgen-dependent genes. 
To identify the USP7-regulated AR target gene, the gene exhibited at least 1.5 fold 
alteration after DHT stimulation (relative to vehicle) were filtered as androgen- 
dependent genes. According to this, 332 genes were defined as DHT up-regulated and 
189 genes were defined as DHT down-regulated, the others (10938) were define as stable. 
Meanwhile, the gene exhibited greater than 1.5 fold alteration by USP7 knockdown 
(relative to mock) were filtered as USP7-regulated (Figure 3-12). The overlapping genes 
between USP7-regulated and androgen-dependent were represented using Venn 
diagram (Figure 3-13). 
In the absence of DHT, total 705 genes were differently expressed by USP7 knockdown 
including 399 down-regulated and 306 up-regulated, revealing the wide range of 
biological effects by which USP7. Among the USP7-regulated genes (including down- and 
up- regulated), approximately 30% overlapped with androgen-dependent (including 
down- and up- regulated), suggesting these overlapping genes were regulated 
independent of AR signaling (Figure 3-13 A). 
To further observe the USP7 knockdown effect on androgen up-regulated and down-
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regulated gene expression under androgen signaling, respectively. Approximately 54% 
(179 genes) of DHT up-regulated genes were decreased by USP7 knockdown, revealing 
the coactivator role of USP7. Contrast to this, knockdown of USP7 derepressed 28% (54 
genes) of DHT down-regulated genes (Figure 3-13 B), implying the corepressor role of 
USP7.  
Given that the mechanism of AR mediated-gene activation is distinct from repression, 
supposing USP7 is involved in AR transcriptional regulation via multiple pathways. 
Although the repression function by which USP7 need to be further verified, the data of 
USP7 trans-repressed the ARE-containing reporter activity supported the corepressor 
role of USP7 (Figure 3-5). This result revealed the requirement of USP7 in androgen-
dependent gene regulation and indicated that USP7 is a gene specific AR coregulator. 
To further confirm the importance of USP7 in androgen-dependent gene expression, I 
compared the effect of USP7 knockdown on DHT-stimulated gene expression. 
Knockdown of USP7 significantly abolished the DHT induction fold among androgen-
dependent gene (down-regulated and up-regulated) but not stable, revealing the 
essential role of USP7 in androgen-dependent gene regulation (Figure 3-14).  
The result of RNA-seq analysis was validated by qPCR to examine several androgen-
activated genes including PSA, FKBP5 and PDE9A (Figure 3-15, 3-16), as well as 
androgen-repressed genes such as BMF and SLC44A1 (Figure 3-17).  
The RNA-seq analysis of transcriptome profiling shown that USP7 affected a subset 
of androgen-dependent gene expression, to assess the biological function of USP7 in 
androgen signaling, the overlapping genes between androgen-dependent and USP7-
regulated were subjected to gene ontology (GO) analysis using DAVID.  
The analysis of the 179 overlapping gene between androgen up-regulated and USP7-
regulated gene exhibited significantly enriched within several biological process 
including DNA replication and cell cycle regulation (Figure 3-18) revealing the essential 
role of USP7 in androgen signaling. 
Together, these data exhibited the essential role of USP7 in AR transcriptional 
regulation, and is important for a specific subset of androgen-dependent gene expression 
that are highly associated with several androgen-mediated biological process such as 
DNA replication.  
 
5. USP7 facilitates AR chromatin recruitment 
Although the transcriptome profiling indicated the gene specific regulation manner of 
USP7, given that the androgen-activated gene expression mechanism is well established, 
the mechanism of USP7 mediates androgen-activated gene expression was investigated. 
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The previous data shown that inhibition and knockdown of USP7 abolished a subset 
of androgen inducible gene mRNA expression including FKBP5, PSA and PDE9A. To 
examine whether this gene expression inhibition results from affecting AR chromatin 
binding. The effect of USP7 inhibitor P22077 on AR recruitment to FKBP5 gene AREs 
was observed. Consistent with the mRNA expression, the recruitment of AR to FKBP5 
gene AREs was reduced (Figure 3-19 A). In addition, USP7 knockdown also abolished 
the binding of AR to FKBP5, PSA and PDE9A gene AREs (Figure 3-19 B), supposing 
USP7 mediates AR transcriptional activity by facilitating AR chromatin recruitment. 
 
6. USP7 regulates liganded AR protein stability 
The data of USP7 overexpression attenuated ubiquitinated AR that generated by DHT, 
supposing USP7 may be involved in receptor stabilization thereby facilitates AR 
chromatin recruitment. To investigate whether USP7 mediates AR protein stability, the 
effect of USP7 overexpression on wt-AR protein degradation rates in the absence or 
presence of DHT was observed. The protein synthesis inhibitor cycloheximide (CHX) was 
added in 293T cells, and the wt-AR protein degradation rates were visualized using 
immunoblotting(Figure 3-20).  
The result revealed that overexpression of USP7 was without obvious effect on AR 
protein stability in the absence of DHT. Upon DHT stimulation, the liganded AR protein 
half-life was significantly prolonged in USP7 overexpression cells, suggesting USP7 is 
involved in liganded AR protein stability regulation. 
 
7. USP7 is required for prostate cancer LNCaP cell proliferation 
It is well accepted that the transcriptional output of AR contribute to prostate cancer 
cell proliferation. Given the essential role of USP7 in androgen-dependent gene 
expression, suggesting USP7 may regulate prostate cancer cell proliferation. To assess 
the biological function of USP7 in androgen-stimulated prostate cancer cell growth, the 
cell proliferation assay was performed in USP7 knockdown LNCaP cells.  
The result displayed that DHT-stimulated cell growth was severely diminished by 
USP7 knockdown (Figure 3-21). In addition, knockdown of USP7 also attenuated the cell 
growth in the absence of DHT, suggesting USP7 can regulate prostate cancer cell 
proliferation through AR-independent pathway. Consider to the RNA-seq analysis of 
USP7 knockdown affected wide range of gene expression independent of AR, implying 
USP7 can mediate prostate cancer cell proliferation through AR-dependent and -
independent signaling. 
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Summary 
 
  In this chapter, the functional role of USP7 in AR transcriptional regulation was 
investigated. Upon DHT stimulation, USP7 was recruited to AREs and cooperated with 
AR to regulate gene transcription. The result of transcriptome profiling in LNCaP cells 
revealed the essential role of USP7 in androgen-dependent gene expression, 
approximately 54% of androgen up-regulated gene were affected by USP7 knockdown. 
Among the androgen inducible genes, USP7 may mediate gene expression via regulation 
of chromatin receptor ubiquitin-proteasomal degradation and facilitate AR chromatin 
binding. 
In addition, among androgen down-regulated gene, 28% were derepressed by USP7 
knockdown, although the exact role of USP7 in androgen down-regulated gene need to 
be further verified. The result suggested the gene specific regulation manner of USP7. 
This study not only exhibits the comprehensive role of USP7 in AR transcriptional 
regulation but also broadens the perspective of ubiquitin network in AR actions.  
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Figure 3-1 The time course recruitment of AR and USP7 to PSA, FKBP5 and 
PDE9A gene AREs 
LNCaP cells were treated with 10 nM DHT for 0, 1, 4, 16 h and the DNA bound to AR 
(A) and USP7 (B) were measured by ChIP-qPCR. 
 
 
 
 
 
 
(A) 
(B) 
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Figure 3-2 USP7 associates with AR on FKBP5 and PSA gene AREs is 
DHT-dependent enhanced 
The Re ChIP assay was performed in DHT-treated 1 h LNCaP cells using anti-AR 
antibody and followed with second-round antibodies as indicated. 
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Figure 3-3 The recruitment of AR to AREs is attenuated by AR antagonist 
in LNCaP cells 
LNCaP cells were pretreated with bicalutamide (Bic) 10 μM for 2 h and then 
treated with EtOH or DHT for 4 h. The ChIP-qPCR was performed using anti-AR 
antibody to observe the AR recruitment to PSA, PDE9A and FKBP5 gene. The 
random DNA sequence near the PSA and FKBP5 AREs were used as negative 
control.( **, p<0.01, two-tailed t-test)  
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Figure 3-4 The recruitment of USP7 to AREs is attenuated by AR 
antagonist in LNCaP cells 
LNCaP cells were pretreated with bicalutamide (Bic) 10 μM for 2 h and then treated 
with EtOH or DHT for 4 h. The ChIP-qPCR was performed using anti-USP7 antibody 
to observe the USP7 recruitment to PSA, PDE9A and FKBP5 gene. (**, P<0.01, two-
tailed t-test) 
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Figure 3-5 USP7 squelches AR-dependent transcription from an ARE-
regulated Luciferase reporter 
(A) 293T cells were transfected with plasmids as indicated for 24 h and followed by 
18 h DHT treatment. The cell lysate were subjected to luciferase assay.  (B) 293T cells 
were transfected USP7 siRNA for 72 h and followed by plasmids as indicated 
transfection for 24 h and subsequently treated with 10 nM DHT for 18 h before cell 
harvested. The cell lysate were subjected to luciferase assay. Data is shown relative to 
wt- AR transfected alone whose value was set at 1. **, p<0.01, two-tailed t-test) 
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Figure 3-6 Validation the time course of AR-target genes mRNA expression 
stimulated by 10 nM DHT in LNCaP cells 
LNCaP cells were maintained in phenol-red free medium with 5% CCS for 72 h and 
treated with 10 nM DHT for indicated time periods. The cells were harvested and the 
isolated RNA were measured using qPCR. 
 
 
 
 
58 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-7 Effect of USP7 inhibitor P22077 on DHT-activated AR target 
genes mRNA expression 
  The mRNA expression level of AR-target genes PSA, FKBP5 and CLDN8 in LNCaP 
cells were determined by qPCR and normalized against expression level of the 
GAPDH gene in the absence or presence of DHT for 8 h upon pretreated with USP7 
inhibitor P22077 with 10 uM or 20 uM for 30 min, respectively. (**, p<0.01, ***, 
p<0.001, two-tailed t-test) 
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Figure 3-8 Validation of the three USP7 siRNA oligonucleotides 
(A) Immunoblotting confirming the knockdown of USP7 protein in LNCaP cells  
transfected with three specific USP7 siRNA. (B) Validation of three USP7 siRNA 
effect on PSA mRNA expression using qPCR. ***, P<0.001, two-tailed t-test. 
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Figure 3-9 (A) The scheme of sample preparation for RNA-seq analysis (B) 
Validation of protein expression 
(A) LNCaP cells were transfected with USP7 siRNA for 72 h and incubated in  
10 nM DHT medium for 16 h. RNA was isolated and subjected to RNA-seq analysis. 
(B) The protein expression in sample (A) was examined using immunoblotting. 
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Figure 3-10 Heatmap representation of global genes expression profile by 
RNA-seq analysis 
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Figure 3-11 Heatmap representation of androgen-dependent genes 
expression profile by RNA-seq analysis 
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Figure 3-12 Workflow of androgen-dependent genes and USP7-regulated 
genes identification 
To identify the USP7-dependent AR target genes, the genes exhibited at least 1.5 
fold expression alteration after DHT stimulation were filtered as androgen-dependent 
genes. Meanwhile, the genes exhibited greater than 1.5 fold expression alteration by 
USP7 knockdown were filtered as USP7-regulated genes. The number in the brackets 
are gene number. 
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Figure 3-13 The overlap between USP7-regulated and androgen-
dependent genes 
(A-B) Venn diagram showing the overlap between USP7-regulated genes and 
androgen-dependent genes in the absence (A) or in the presence (B) of DHT. The 
number in the brackets are gene number. USP7 siRNA-down: genes that expression 
attenuated by USP7 knockdown, USP7 siRNA-up: genes that expression increased 
by USP7 knockdown 
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Figure 3-14 Boxplot showing the DHT induction fold change in mock and 
USP7 knockdown cells 
Among the androgen-dependent genes, the DHT induction fold change is 
significantly affected by USP7 knockdown. P value are calculated using two-tailed t- 
test.  
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Figure 3-15 Validation of the RNA-seq result-1: androgen-activated genes  
The mRNA expression level of androgen up-regulated genes in USP7 knockdown 
LNCaP cells were determined by qPCR and normalized against expression level of 
the GAPDH gene in the absence or presence of DHT for 8 h.  
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Figure 3-16 Validation of the RNA-seq result-1: androgen-activated genes  
The mRNA expression level of androgen up-regulated genes in USP7 knockdown 
LNCaP cells were determined by qPCR and normalized against expression level of 
the GAPDH gene in the absence or presence of DHT for 16 h. *, p<0.05, **, p<0.01, ***, 
p<0.001, two-tailed t-test. 
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Figure 3-17 Validation of RNA-seq result-2: androgen-repressed genes 
The mRNA expression level of androgen down-regulated genes in USP7 knockdown 
LNCaP cells were determined by qPCR and normalized against expression level of 
the Actin gene in the absence or presence of DHT for 16 h.**, p<0.01, two-tailed t-test. 
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Figure 3-18 Functional annotation suggested that USP7 is involved in 
androgen-regulated biological function  
Functional annotation of the 179 overlapping genes between DHT up-regulated and 
USP7 siRNA down-regulated genes using DAVID. Top overrepresented gene 
categories (p<0.05) from gene ontology (GO) biology process are shown. 
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Figure 3-19 USP7 facilitates AR chromatin recruitment 
(A) USP7 inhibitor P22077 inhibited AR recruitment to FKBP5 AREs. LNCaP cells  
were pretreated with P22077 (20 μM) for 30 min and then treated with 10 nM DHT 
or EtOH for 4 h. The ChIP-qPCR was performed using anti-AR antibody. (B) The 
recruitment of AR to AREs were diminished by USP7 knockdown. LNCaP cells were 
transfected with USP7 siRNA for 72 h and then treated with EtOH or 10 nM DHT for 
1 h. The ChIP-qPCR was performed using anti-AR antibody. *, p<0.05, ***, p<0.001, 
two-tailed t-test. 
  
(A) 
(B) 
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Figure 3-20 USP7 is involved in AR protein stability regulation 
293T cells were transfected with AR and Flag-USP7 expression vectors for 24 h and 
added 10 nM DHT for 2 h followed by 150 μg/ml cycloheximide (CHX) time course 
treatment before cell harvested. Quantification of AR levels were carried out using 
densitometry by normalizing AR to -Tubulin expression (bottom panel). Values were 
set relative to AR expression at time 0. The mean + SD values of three independent 
experiment. 
72 
 
     
Figure 3-21 USP7 is required in androgen-stimulated LNCaP prostate 
cancer cell proliferation 
LNCaP cells were transfected with USP7 siRNA for 24 h, and subsequently seeded 
in 12 well plate. The cells were incubated in hormone starvation condition in the 
absence or presence of 10 nM DHT, and the cell number of each well were counted at 
indicated time. 
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Chapter 4 
Conclusion and Discussion 
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Conclusion 
 
  This study was endeavored to reveal a novel AR transcriptional regulation mechanism 
by identifying the composition of AR transcriptional protein complexes. For this purpose, 
the AR-associated proteins were affinity purified and the high score candidate USP7 was 
focused. Through investigating the functional role of USP7 in AR transcriptional 
regulation, a new insight of ubiquitin network was brought into in AR transcriptional 
regulation.  
 
1. The proposal mechanism of USP7 regulates AR transcriptional activity 
From this study, the molecular mechanism of USP7 mediates androgen-regulated 
genes especially activated genes expression can be proposed: 
USP7 is associated with AR on AREs upon rapid DHT stimulation, where USP7 acts 
as guard to protect AR from ubiquitin/ proteasomal degradation thereby facilitates a 
subset of target genes expression that associate with several androgen-mediated 
biological processes. While USP7 deubiquitinates AR directly or indirectly need to be 
clarified (Figure 4-1). 
 
2. The gene specific regulation manner of USP7 in androgen-dependent 
genes 
To profile the USP7 knockdown effect on genome-wide androgen-dependent gene 
transcripts, revealing the essential role of USP7 in androgen-dependent genes regulation 
and the gene specific regulation manner by which USP7. While USP7 acts as a 
coactivator is much more impressive than corepressor, and the exact function of USP7 in 
androgen-repressed genes need to be verified. The data of USP7 trans-repressed the 
ARE-containing reporter activity supported the corepressor role of USP7. Given that AR 
mediates gene activation and repression via distinct mechanisms, implying USP7 might 
be involved in multiple levels of AR transcriptional regulation. While this speculation 
remain to be corroborated, this analysis impressed the importance of ubiquitin network 
in AR transcriptional activity and specificity regulation. 
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Discussion 
 
1. The role of USP7 in ubiquitin network-regulated AR transcriptional 
activity 
Hormone regulated ubiquitination of AR results in intricate effects on AR 
transcriptional activity, and vice versa deubiquitination of AR by USP7 also brings many 
possible consequences in AR transcriptional regulation. 
The result of liganded AR protein half-life was prolonged by overexpression of USP7 
suggested that USP7 is involved in hormone-regulated receptor ubiquitination and 
proteasomal degradation. The chromatin ubiquitin-proteasome system is supposed to 
allow proper progression through rounds of transcription and appropriate assembly of 
the necessary protein complexes as well as modulates the activation status of 
transcription factors and coregulators. On the other hand, RNF6 generates Lys 6- and 
Lys 27-linked Ub chains that stabilize AR receptor and act as scaffold for coactivators 
such as ARA54 recruitment, thereby regulates AR transcriptional activity and specificity. 
Hence, the DUBs activity of USP7 is possible to oppose these E3 ligase actions and blocks 
gene transcription. 
This situation can be solved through mediation of the short-term USP7 recruitment to 
chromatin. By strictly controlling these ubiquitin network enzymes dynamic association 
and disassociation sequence and duration, the AR transcriptional activity can be 
precisely regulated. Similar mechanism was also described in the studies of TSG101 and 
USP26 in AR transcriptional activity regulation. TSG101 is proposed to maintain AR in 
monoubiquitination state by preventing AR polyubiquitination and stimulating AR 
transcriptional activity. Another DUBs USP26 is proposed to reverse MDM2-generated 
ubiquitination chains, and extend transcriptional activation. 
It was reported that the interaction between E3 ligase and DUBs allow fine-tuning of 
the ubiquitination status of common substrates38. The well know case is the E3 ligase 
MDM2 and its substrate P53 are relevant USP7 substrates. USP7 can both remove 
ubiquitin from MDM2 and its substrate P53, thereby both stabilizes P53 and MDM2. 
Through the coupling of positive and negative ubiquitin regulation, the cell P53 protein 
level are precisely and strictly controlled. This working model may be utilized to fine-
tuning of the AR ubiquitination status and affect AR quantitative /qualitative regulation. 
The well characterized AR E3 ligase MDM2 and RNF6 may cooperate with USP7 to 
regulated AR transcriptional activity.  
Although the dynamic interplay between USP7 and other ubiquitin network enzymes 
remain to be clarified, this study not only impress the importance of DUBs in AR 
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transcriptional activity and specificity regulation but also broaden the view of ubiquitin 
network in gene regulation. 
 
2. The proposal mechanism of USP7 mediated androgen-dependent gene 
repression 
The result of globally profile the USP7 knockdown effect on genome-wide transcript 
not only revealed the coactivator role of USP7 in up-regulated genes but also showing 
28% of DHT down-regulated genes were derepressed by USP7 knockdown and proposing 
the USP7 corepressor role. 
The mechanism of AR-mediated gene repression versus activation is fundamental 
different. Although the mechanism of AR activates gene transcription is well established, 
the mechanisms by which AR-mediated gene repression are ill-defined. Several 
mechanisms of AR-repressed gene have been proposed including inhibition of other 
transcription factors/ activators and AR non-genomic actions as well as the direct 
binding of AR to negative AREs (nAREs)55.  
While the DNA consensus sequence specific for negative regulation by androgens has 
not yet been described. The binding of AR to nAREs is supposed resulting in 
displacement of RNA Polymerase II and formation of corepressor complexes which 
contribute to a more condensed chromatin conformation thereby represses gene. The 
data of USP7 squelches DHT-stimulated ARE-luciferase reporter activity suggested that 
USP7 regulates androgen-repressed gene through mediating the binding of AR to DNA/ 
nAREs.  
It is supposed that enhancers are specified by particular chromatin marks by which 
cells establish patterns of gene expression. On the other hand, USP7 was reported to 
modulate histone H2A ubiquitinase Polycomb repressive complex 1 (PRC1) and DNA 
methyltransferase 1 (DNMT1)-suppressed gene expression56,57. Even USP7 itself was 
supposed to function as a histone H2B deubiquitinase and repress gene in insect cells58.    
As a result, USP7 might cooperate with the enhancer specific epigenetic enzymes 
network to modulate the enhancer epigenetic environment thereby destine gene 
activation or repression.  
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Perspective  
 
USP7 is a potential therapeutic target in prostate cancer 
 
The aberrant AR signaling mediate the initiation and progression of ADPC as well as 
the development of HRPC. To clarify the mechanism by which manipulation the AR 
transcriptional activity in ADPC and HRPC is important for prostate cancer therapy.  
Several hyperactive AR signaling mechanism have been proposed, including AR 
receptor point mutation, AR gene amplification and aberrant expression of coregulators. 
Recent studies have shown that altered expression of AR coregulators such as SRC and 
p300 in prostate cancer may modify AR transcriptional activity and can be utilized as 
prostate cancer diagnosis mark. 
Here, the DUBs USP7 was biochemically identified as a novel AR coregulator in 
prostate cancer, and is required for AR transcriptional activity and specificity. This study 
implicated the importance of USP7 in prostate cancer progression. Indeed, previous 
study has observed the overexpression of USP7 in human prostate cancer, and the high 
levels USP7 is involved in the aberrant PTEN nuclear exclusion regulation as well as 
directly correlated with tumor aggressiveness52. 
Taken together, these data suggested that USP7 can manipulate AR-dependent and -
independent signaling to promote prostate cancer progression. Recent years, many USP7 
specific small molecular inhibitors have been discovered for cancer target therapy such 
as colon cancer59,60. This study exhibits that USP7 mediates AR transcriptional activity 
and specificity as well as involved in AR-dependent and –independent cell proliferation. 
As a result, USP7 may also be as a potential target for prostate cancer therapy. 
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Figure 4-1 Conclusion-Model of USP7 regulates AR transcriptional activity 
Upon androgen stimulation, liganded AR, USP7 and other coregulators are 
recruited to AREs. USP7 protects AR from ubiquitin-targeted proteasomal 
degradation and activates a subset of androgen-dependent gene expression that highly 
associate with androgen-mediated biological processes such as cell cycle regulation. 
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Figure 4-2 Discussion-The proposed working model of USP7 and AR E3 
ligase to fine-tuning AR quantitative /qualitative regulation. 
The DUBs USP7 and E3 ligase such as RNF6 and MDM2 may cooperate to fine-
tuning AR ubiquitination status. Through the coupling of positive and negative 
ubiquitin regulation, the AR protein level and transcriptional activity are able to be 
precisely and strictly controlled. 
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Figure 4-3 Perspective-USP7 mediates prostate cancer cell progression via 
AR-dependent and AR-independent signaling 
  The overexpression USP7 in prostate cancer is involved in hyperactive AR signaling 
and aberrant PTEN nuclear exclusion, thereby promote prostate cancer cell 
proliferation and progression. Consequently, USP7 might be a potential target for 
prostate cancer therapy. 
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